Oncogenic osteomalacia: loss of hypophosphatemia might be the key to avoid misdiagnosis

• Autor(a) principal: Chang, Claudia V.
• Data de Publicação: 2012
• Outros Autores: Conde, Sandro J., Luvizotto, Renata A. M., Nunes, Vânia S., Bonates, Milla C., Felício, André Carvalho [UNIFESP], Lindsey, Susan C., Moraes, Flávia H., Tagliarini, José V., Mazeto, Glaucia M. F. S., Kopp, Peter, Nogueira, Célia R.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S0004-27302012000800018; http://repositorio.unifesp.br/handle/11600/7376

Diagnosing oncogenic osteomalacia is still a challenge. The disorder is characterized by osteomalacia caused by renal phosphate wasting and low serum concentration of 1,25-dihydroxyvitamin D3 occurring in the presence of a tumor that produces high levels of fibroblast growth factor 23. However, it is possible that the disease is much more misdiagnosed than rare. We present the case of a 42-year-old man with a long-term history of undiagnosed progressive muscle weakness. His laboratory results mainly showed low serum phosphate. Surgical removal of a nasal hemangiopericytoma that had been diagnosed five years earlier, brought him to a symptom-free condition. Even though knowing the underlying etiology would explain his osteomalacia, the patient sought medical help from countless physicians for five consecutive years, and only after adequate treatment a rewarding outcome was achieved. Arq Bras Endocrinol Metab. 2012;56(8):570-3